Key result
Low-molecular-weight heparin treatment during pregnancy in women with inherited thrombophilia resulted in 0% fetal loss compared to 76.9% in their previous untreated pregnancies.
Why the study?
Does LMWH improve pregnancy outcomes in women with inherited thrombophilia and a history of thromboembolic events or poor obstetric outcomes?
Cohort (n=38)
Does LMWH improve pregnancy outcomes in women with inherited thrombophilia and a history of thromboembolic events or poor obstetric outcomes?
LMWH treatment during pregnancy in women with inherited thrombophilia and prior poor obstetric outcomes or thromboembolic events significantly improves fetal survival and birth weight without increasing bleeding risk.
Answers are grounded in this paper and cite their sources.
May support LMWH consideration in high-risk thrombophilia pregnancies; leaves open confirmation by randomized trials before practice change.
OBJECTIVE: Inherited thrombophilia is associated with thromboembolic events and/or poor obstetric outcome. We evaluated the pregnancy outcome in women with inherited thrombophilia treated with low-molecular-weight heparin (LMWH). METHODS: 38 thrombophilic women with a history of thromboembolic events and/or poor obstetric outcome were treated during their 39 consecutive pregnancies with LMWH from pregnancy verification until 4-6 weeks in puerperium. A fixed dose of enoxaparin 4,000 IU/day (except 1 case who required nadroparin 0.3 ml/day) was administered in most cases, adopting a higher dose (6,000 IU/day to 6,000 IU twice a day) in those with previous thromboembolic events. RESULTS: In the treated women, all had a good obstetric outcome, whereas in the previous untreated pregnancies (n = 78), the rate of fetal loss (early and late) was 76.9%, only 12 live infants survived (66.6%). Moreover, birth weight resulted significantly higher in live infants born to treated pregnancies in comparison to that of previous untreated pregnancies (p = 0.009). No maternal thrombosis or major bleeding complications were recorded. CONCLUSIONS: The treatment with LMWH improved pregnancy outcome resulting effective and safe in thrombophilic women with a history of thromboembolic events and/or poor obstetric outcome.
No takes yet. Share an insight, caveat, or question.
Carolis et al. (2006) conducted a cohort in Inherited thrombophilia (n=38). Low-molecular-weight heparin (LMWH) vs. Previous untreated pregnancies was evaluated on Fetal loss (early and late). Low-molecular-weight heparin treatment during pregnancy in women with inherited thrombophilia resulted in 0% fetal loss compared to 76.9% in their previous untreated pregnancies.
Synapse has enriched 10 related papers. Consider them for comparative context: